References
Tangrea JA, Albert PS, Lanza E, et al. (2003) Non-steroidal antiinflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control 14: 403-411.
Schatzkin A, Lanza E, Corle D, et al. (2000) Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342: 1149-1155.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
Langenbach R, Morham SG, Tiano HF, et al. (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acidinduced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492.
DuBois RN, Radhika A, Reddy BS, Entingh AJ (1996) Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110: 1259-1262.
Williams CS, Luongo C, Radhika A, et al. (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111: 1134-1140.
Shiff SJ, Koutsos MI, Qiao L, Rigas B (1996) Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222: 179-188.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716.
Jacoby RF, Marshall DJ, Newton MA, et al. (1996) Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56: 710-714.
Boolbol SK, Dannenberg AJ, Chadburn A, et al. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556-2560.
Barnes CJ, Lee M (1998) Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114: 873-877.
Piazza GA, Rahm AL, Krutzsch M, et al. (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116.
Piazza GA, Alberts DS, Hixson LJ, et al. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57: 2909-2915.
Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686.
Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV (1999) Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 59: 3387-3391.
Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959.
He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
Shureiqi I, Chen D, Lotan R, et al. (2000) 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60: 6846-6850.
Labayle D, Fischer D, Vielh P, et al. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639.
Giardiello F, Hamilton S, Krush A, Piantadosi S (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1231-1235.
Steinbach G, Lynch PM, Phillips RK, et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952.
Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404.
Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72: 1171-1177.
Peleg II, Maibach HT, Brown SH, Wilcox CM (1994) Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154: 394-399.
Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM (1996) Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 41: 1319-1326.
Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL (1996) Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 5: 955-960.
La Vecchia C, Negri E, Franceschi S, et al. (1997) Aspirin and colorectal cancer. Br J Cancer 76: 675-677.
Rosenberg L, Louik C, Shapiro S (1998) Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 82: 2326-2333.
Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355-358.
Muscat JE, Stellman SD, Wynder EL (1994) Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 74: 1847-1854.
Muller AD, Sonnenberg A, Wasserman IH (1994) Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci 39: 2480-2484.
Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L (1999) Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81: 62-68.
Coogan PF, Rosenberg L, Louik C, et al. (2000) NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control 11: 249-255.
Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320: 1642-1646.
Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146.
Thun M, Calle E, Namboodiri M, Heath C (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596.
Giovannucci E, Egan KM, Hunter DJ, et al. (1995) Aspirin and the risk of colorectal cancer in women. N Engl JMed 333: 609-614.
Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159: 161-166.
Garcia-Rodriguez LA, Huerta-Alvarez C (2001) Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 12: 88-93.
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246.
Logan RF, Little J, Hawtin PG, Hardcastle JD (1993) Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 307: 285-289.
Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT (1998) Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 114: 441-447.
Breuer-Katschinski B, Nemes K, Rump B, et al. (2000) Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 61: 129-134.
Martin C, Connelly A, Keku TO, et al. (2002) Nonsteroidal antiinflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology 123: 1770-1777.
Martinez ME, McPherson RS, Levin B, Annegers JF (1995) Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 4: 703-707.
Garcia Rodriguez LA, Huerta-Alvarez C (2000) Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 11: 376-381.
Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299: 1247-1250.
Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85: 1220-1224.
Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH (1998) Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128: 713-720.
Greenberg E, Baron J, Freeman D (1993) Reduced risk of large bowel adenomas among aspirin users. J Natl Cancer Inst 85: 1593-1596.
Baron JA, Cole BF, Sandler RS, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899.
Sandler RS, Halabi S, Baron JA, et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890.
Frommel TO, Dyavanapalli M, Oldham T, et al. (1997) Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients. Clin Cancer Res 3: 209-213.
Ruffin MT, Krishnan K, Rock CL, et al. (1997) Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 89: 1152-1160.
Chow HH, Earnest DL, Clark D, et al. (2000) Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. Cancer Epidemiol Biomarkers Prev 9: 351-356.
Sample D, Wargovich M, Fischer SM, et al. (2002) A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev 11: 275-279.
Patrono C, Coller B, Dalen JE, et al. (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119: 39S-63S.
Reddy BS, Maruyama H, Kelloff G (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 47: 5340-5346.
Ricchi P, Pignata S, Di Popolo A, et al. (1997) Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Int J Cancer 73: 880-884.
Spencer RJ, Melton LJ, 3rd Ready RL, Ilstrup DM (1984) Treatment of small colorectal polyps: a population-based study of the risk of subsequent carcinoma. Mayo Clin Proc 59: 305-310.
Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101: 1206-1218.
Imperiale TF (2003) Aspirin and the prevention of colorectal cancer. N Engl J Med 348: 879-880.
Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF (1996) Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 156: 1530-1536.
Larkai EN, Smith JL, Lidsky MD, Graham DY (1987) Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82: 1153-1158.
Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26: 18-24.
The Dutch TIA Trial Study Group (1991) A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325: 1261-1266.
Farrell B, Godwin J, Richards S, Warlow C (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54: 1044-1054.
Roderick PJ, Wilkes HC, Meade TW (1993) The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 35: 219-226.
Weil J, Colin-Jones D, Langman M, et al. (1995) Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310: 827-830.
Iso H, Hennekens CH, Stampfer MJ, et al. (1999) Prospective study of aspirin use and risk of stroke in women. Stroke 30: 1764-1771.
Curhan GC, Willett WC, Rosner B, Stampfer MJ (2002) Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 162: 2204-2208.
Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC (2002) Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 40: 604-608.
Fored CM, Ejerblad E, Lindblad P, et al. (2001) Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 345: 1801-1818.
Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321: 1183-1187.
Giardiello FM, Yang VW, Hylind LM, et al. (2002) Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059.
MMWR (2001) Trends in screening for colorectal cancer-United States, 1997 and 1999. Morb Mortal Wkly Rep 50: 162-166.
Hu FB, Manson JE, Liu S, et al. (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91: 542-547.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chan, A.T. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 14, 413–418 (2003). https://doi.org/10.1023/A:1024986220526
Issue Date:
DOI: https://doi.org/10.1023/A:1024986220526